Clinical Trial Applications - Stopped: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Stopped | |
|---|---|---|---|---|---|
11. |
ECCT/17/06/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) 2. KAVI Institute of Clinical Research (Nairobi City county) |
Not recorded |
View |
12. |
ECCT/17/08/04 | P1081 A PHASE IV RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN INITIATING TRIPLE ANTIRETROVIRAL REGIMENS BETWEEN 28 AND 36 WEEKS OF PREGNANCY FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION: NICHD P1081 |
Principal Investigator(s) 1. FREDRICK KIPYEGON SAWE Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre. |
Not recorded |
View |
13. |
ECCT/17/09/02 | WHO ACTION-I and ACTION-2 Trial A65913: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes A65916: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes |
Principal Investigator(s) 1. Frederick Were 2. John Kinuthia 3. Zahida Parveen Qureshi 4. Zahida Parveen Qureshi 5. Zahida Parveen Qureshi Site(s) in Kenya 1. Coast Provincial General Hospital (Mombasa Level 5 Hospital) (Mombasa county) 2. Kiambu Level 4 Hospital (Kiambu county) 3. Thika Level 5 Hospital (Kiambu county) 4. Nakuru Level 5 Hospital (Nakuru county) |
Not recorded |
View |
14. |
ECCT/17/09/03 | A5354 Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses |
Principal Investigator(s) 1. Deborah Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre |
Not recorded |
View |
15. |
ECCT/18/05/03 | RV 392 Antiretroviral Therapy for Acute or Early HIV Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya KEMRI WRP, Kericho |
Not recorded |
View |
16. |
ECCT/18/07/05 | A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo |
Principal Investigator(s) 1. Fredrick Sawe 2. Janet Oyieko Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Centre (Kericho county) 2. KEMRI/WRP Kisumu, Kenya at the Kombewa Clinical Research Centre (Kisumu county) |
Not recorded |
View |
17. |
ECCT/18/07/06 | Hestia 3 A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Prof Jessie Nyokabi Githanga 2. Videlis Nduba 3. Janet N Oyieko 4. Bernards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Chandaria Health Center Clinical Research Clinic (Nairobi City county) 3. Kenya Medical Research Institute (KEMRI) Kisumu (Kisumu county) 4. KEMRI Kombewa Clinical Research Centre (Nairobi City county) 5. Kondele Children\'s Hospital (Kisumu county) 6. Strathmore University Medical Centre (Nairobi City county) |
Not recorded |
View |
18. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
Not recorded |
View |
19. |
ECCT/19/08/01 | Use of malaria infection by injection to study malaria transmission Safety and feasibility of a malaria transmission model in semi-immune Kenyan adults using Plasmodium falciparum sporozoites |
Principal Investigator(s) 1. Melissa Kapulu 2. Philip Bejon Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
Not recorded |
View |
20. |
ECCT/19/12/02 | VPM1002 Phase III PoI A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI-CRDR Nairobi (Nairobi City county) 2. KEMRI-CRDR Siaya (Siaya county) |
Not recorded |
View |